Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Kevin_Ali
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focus |
biosimilars
women's health established medicines |
| gptkbp:founded |
2021
|
| gptkbp:headquarters_location |
gptkb:Jersey_City,_New_Jersey,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Organon (2021 spin-off)
|
| gptkbp:industry |
gptkb:drug
|
| gptkbp:notableProduct |
gptkb:Follistim_AQ
gptkb:Ganirelix_Acetate_Injection gptkb:Nexplanon gptkb:NuvaRing Biosimilars portfolio |
| gptkbp:numberOfEmployees |
~9,000 (2021)
|
| gptkbp:origin |
spin-off from Merck & Co.
|
| gptkbp:parentOrganization |
gptkb:Merck_&_Co._(prior_to_spin-off)
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockExchange |
gptkb:NYSE
|
| gptkbp:stockSymbol |
gptkb:OGN
|
| gptkbp:website |
https://www.organon.com/
|
| gptkbp:bfsParent |
gptkb:MSD_(outside_United_States_and_Canada)
|
| gptkbp:bfsLayer |
5
|